Insights | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Pro Bono Partner Organizations

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Blog | May 01, 2014

"A" does not mean "one or more" when such construction leads to an absurd result

Blog | April 30, 2014

Decision whether to institute inter partes review is not reviewable

Blog | April 30, 2014

Assignment during inter partes reexam removes ability of former patent owner to appeal

Blog | April 29, 2014

Today's Supreme Court decisions may impact NPE cases related to attorney fees

Blog | April 29, 2014

Supreme Court loosens standards for fee-shifting in patent actions

Blog | April 29, 2014

Later-Issued patent that expires before earlier-issued patent can serve as a double patenting reference

Blog | April 29, 2014

Limelight v. Akamai: A software case worthy of biotech's attention

Blog | April 29, 2014

Excluding Reply Declarations and Evidence

Blog | April 29, 2014

NDIll addresses EMVR, apportionment, unpatented items in royalty base, and price erosion

Blog | April 28, 2014

Federal Circuit Takes Narrow View of Its Ability to Review PTO Decisions Regarding Whether to Institute Inter Partes Review

Blog | April 27, 2014

Unexpected results cannot rebut showing that treatment was obvious to try

Blog | April 26, 2014

Damages expert evidence based on reliable methods is improperly excluded; no per se rule precluding injunctions for SEPs